Vascular Smooth-Muscle-Cell Activation. Proteomics Point of View

International Review of Cell and Molecular Biology

Volumn 288, Issue , 2011, Pages 43-99

  Cecchettini, Antonella ^a,b   Rocchiccioli, Silvia ^a   Boccardi, Claudia ^a   Citti, Lorenzo ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Biomarker discovery; Cardiovascular disorders; Gene therapy; Phenotype proteomics; Target validation; Vascular smooth muscle cells

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA;

ATHEROSCLEROSIS; BLOOD VESSEL INJURY; BOOK; CELL ACTIVATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; GENE SILENCING; HUMAN; MODULATION; NONHUMAN; PHENOTYPE; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEOMICS; RESTENOSIS; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 79953804545     PISSN: 19376448     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386041-5.00002-9     Document Type: Chapter

References (237)

1. Abouhamed M., Reichenberg S., Robenek H., Plenz G. Tropomyosin 4 expression is enhanced in dedifferentiating smooth muscle cells in vitro and during atherogenesis. Eur. J. Cell Biol. 2003, 82:473-482.
2. Adam P.J., Regan C.R., Hautmann M.B., Owens G.K. Positive and negative acting krupple-like transcription factors bind a transforming growth factor beta control element required for expression of the smooth muscle differentiation marker SM22alpha in vivo. J. Biol. Chem. 2000, 275:37798-37806.
3. Aebersold R., Mann M. Mass spectrometry-based proteomics. Nature 2003, 422:198-207.
4. Ahmed N., Barker G., Oliva K., Garfin D., Talmadge K., Georgiou H., et al. An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. Proteomics 2003, 3:1980-7198.
5. Albinsson S., Suarez Y., Skoura A., Offermanns S., Miano J.M., Sessa W.C. MicroRNAs are necessary for vascular smooth muscle growth, differentiation, and function. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1118-1126.
6. Alewijnse A.E., Peters L.M., Michel M.C. Cardiovascular effects of sphingosine-1-phasphate and other sphingomyelin metabolites. Br. J. Pharmacol. 2004, 143:666-684.
7. Allet N., Barrillat N., Baussant T., Boiteau C., Botti P., Bougueleret L., et al. In vitro and in silico processes to identify differentially expressed proteins. Proteomics 2004, 4:2333-2351.
8. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol. 2005, 563:23-60.
9. Apolonia L., Waddington S.N., Fernandes C., Ward N.J., Bouma G., Blundell M.P., et al. Stable gene transfer to muscle ising non-integrating lentiviral vectors. Mol. Ther. 2007, 15:1947-1954.
10. Atkinsons A.J., Colburn W.A., DeGruttola V.G., DeMets D.L., Downing G.J., Hoth D.F., et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Biomarker definition working group. Clin. Pharmacol. Ther. 2001, 69:89-95.
11. Bayer M., Kantor B., Cockrell A., Ma H., Zeithaml B., Li X., et al. A large U3 deletion causes increased in vivo expression from a nonintegrating lentiviral vector. Mol. Ther. 2008, 16:1968-1976.
12. Bell L., Madri J.A. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am. J. Pathol. 1990, 137:7-12.
13. Berk B.C. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol. Rev. 2001, 81:999-1030.
14. Bian Y.L., Qi Y.X., Yan Z.Q., Long D.K., Shen B.R., Jiang Z.L. A proteomic analysis of aorta from spontaneously hypertensive rat: RhoGDI alpha upregulation by angiotensin II via AT1 receptor. Eur. J. Cell Biol. 2008, 87:101-110.
15. Bizzarri M., Cavaliere C., Foglia P., Guarino C., Samperi R., Laganà A. A label-free method based on MALDI-TOF mass spectrometry for the absolute quantitation of troponin T in mouse cardiac tissue. Anal. Bioanal. Chem. 2008, 391:1969-1976.
16. Bjorhall K., Miliotis T., Davidsson P. Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 2005, 5:307-317.
17. Blank R.S., Owens G.K. Platelet-derived growth factor regulates actin isoform expression and growth state in cultured rat aortic smooth muscle cells. J. Cell. Physiol. 1990, 142:635-642.
18. Boccardi C., Cecchettini A., Caselli A., Camici G., Evangelista M., Mercatanti A., et al. A proteomic approach to the investigation of early events involved in vascular smooth muscle cell activation. Cell Tissue Res. 2007, 328:185-195.
19. Bodenmiller B., Mueller L.N., Mueller M., Domon B., Aebersold R. Reproducible isolation of distinct, overlapping segments of the phosphoproteome. Nat. Methods 2007, 4:231-237.
20. Boettger T., Beetz N., Kostin S., Schneider J., Kruger M., Hein L., et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J. Clin. Invest. 2009, 9:2634-2647.
21. Breen D.M., Giacca A. Effects of insulin on the vasculature. Curr. Vasc. Pharmacol. 2010, Sep01, PMID: 20807190.
22. Brisset A.C., Hao H., Camenzind E., Bacchetta M., Geinoz A., Sanchez J.C., et al. Intimal smooth muscle cells of porcine and human coronary artery express S100A4, a marker of the rhomboid phenotype in vitro. Circ. Res. 2007, 10:1055-1062.
23. Brown D.J., Rzucidlo E.M., Merenick B.L., Robert J., Wagner R.J., Martin K.A., et al. Endothelial cell activation of the smooth muscle cell phosphoinositide 3-kinase/Akt pathway promotes differentiation. J. Vasc. Surg. 2005, 41:509-516.
24. Brown X.Q., Bartolak-Suki E., Williams C., Walker M.L., Weaver V.M., Wong J.Y. Effect of substrate stiffness and PDGF on the behavior of vascular smooth muscle cells: implications for atherosclerosis. J. Cell. Physiol. 2010, 225:115-122.
25. Campbell J.H., Campbell G.R. Endothelial cell influences on vascular smooth muscle phenotype. Annu. Rev. Physiol. 1986, 48:295-306.
26. Cantin G.T., Shock T.R., Park S.K., Madhani H.D., Yates J.R. Optimizing TiO2-based phosphopeptide enrichment for automated multidimensional liquid chromatography coupled to tandem mass spectrometry. Anal. Chem. 2007, 79:4666-4673.
27. Celis J.E., Gromov P. 2D protein electrophoresis: can it be perfected?. Curr. Opin. Biotechnol. 1999, 10:16-21.
28. Celis J.E., Gromov P. Proteomics in translational cancer research: toward an integrated approach. Cancer Cell 2003, 3:9-15.
29. Chamley-Campbell J., Campbell G.R., Ross R. The smooth muscle cell in culture. Physiol. Rev. 1979, 59:1-6.
30. Changhui L., Tao S., Fang L., Lanfang L., Xuping Q., Weinan P., et al. PI3K/Akt signaling transduction pathway is involved in rat vascular smooth muscle cell proliferation induced by apelin-13. Acta Biochim. Biophys. Sin. 2010, 42:396-402.
31. Chelius D., Bondarenko P.V. Quantitative profiling of proteins in complex mixtures using liquid chromatography and mass spectrometry. J. Proteome Res. 2002, 1:317-323.
32. Chen H.F., Xie L.D., Xu C.S. The signal transduction pathways of heat shock protein 27 phosphorylation in vascular smooth muscle cells. Mol. Cell. Biochem. 2010, 333:49-56.
33. Cheng J., Du J. Mechanical stretch stimulates proliferation of venous smooth muscle cells through activation of insulin-like growth factor-1 receptor. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1744-1751.
34. Cheng Y., Liu X., Yang J., Lin Y., Xu D.Z., Lu Q., et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ. Res. 2009, 105:158-166.
35. Chiarugi P., Cirri P. Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction. Trends Biochem. Sci. 2003, 28:509-514.
36. Citti L., Rovero P., Colombo M.G., Mariani L., Polisenso L., Rainaldi G. Efficacy of amphipathic oligopeptide to shuttle and release a cis-acting DNA decoy into human cells. Biotechniques 2002, 32:172-177.
37. Clement N., Glorian M., Raymondjean M., Andreani M., Limon I. PGE2 amplifies the effects of IL-1β on vascular smooth muscle cell dedifferentiation: a consequence of the versatility of PGE2 receptors 3 due to the emerging expression of adenylyl cyclase 8. J. Cell. Physiol. 2006, 208:495-505.
38. Cordes K.R., Srivastava D. MicroRNA regulation of cardiovascular development. Circ. Res. 2009, 104:724-732.
39. Cordes K.R., Sheehy N.T., White M.P., Berry E.C., Morton S.U., Muth A.N., et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009, 460:705-710.
40. Cuneo A., Herrick D., Autieri M.V. Il-19 reduces VSMC activation by regulation of mRNA regulatory factor HuR and reduction of mRNA stability. J. Mol. Cell. Cardiol. 2010, 49:647-654.
41. Daemen M.J., Lombardi D.M., Bosman F.T., Schwartz S.M. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ. Res. 1991, 68:450-456.
42. Davies M.G., Owens E.L., Mason D.P., Lea H., Tran K., Vergel S., et al. Effect of platelet-derived growth factor receptor-α and -β blockage on flow-induced neointimal formation in endothelialized baboon vascular grafts. Circ. Res. 2000, 86:779-786.
43. Davis B.N., Hilyard A.C., Nguyen P.H., Lagna G., Hata A. Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype. J. Biol. Chem. 2009, 284:3728-3738.
44. Dengjel J., Kratchmarova I., Blagoev B. Receptor tyrosine kinase signaling: a view from quantitative proteomics. Mol. Biosyst. 2009, 5:1112-1121.
45. DeRuiter M.C., Poelmann R.E., VanMunsteren J.C., Mironov V., Markwald R.R., Gittenberger-de Groot A.C. Embryonic endothelial cells transdifferentiate into mesenchymal cells expressing smooth muscle actins in vivo and in vitro. Circ. Res. 1997, 80:444-451.
46. Di Luozzo G., Bhargava J., Powell R.J. Vascular smooth muscle effect on endothelial cell endothelin-1 production. J. Vasc. Surg. 2000, 31:781-789.
47. Dufour D.R. Lot-to-lot variation in anti-Hepatitis C signal-to-cut-off ratio. Clin. Chem. 2004, 50:101-111.
48. Dupont A., Corseaux D., Dekeyzer O., Drobecq H., Guihot A.L., Susen S., et al. The proteome and secretome of human arterial smooth muscle cells. Proteomics 2005, 5:585-596.
49. Dzau V.J., Braun-Dullaeus R.C., Sedding D.G. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. 2002, 8:1249-1256.
50. Edwards I.L., Aronson J.K. Adverse drug reactions: definitions, diagnosis and management. Lancet 2000, 356:1255-1259.
51. Efthymiou C.A., Mocanu M.M., de Belleroche J., Wells D.J., Latchmann D.S., Yellon D.M. Heat shock protein 27 protects the heart against myocardial infarction. Basic Res. Cardiol. 2004, 99:392-394.
52. Eisenberg M.J., Konnyu K.J. Review of randomized clinical trials of drug-eluting stents for the prevention of in-stent restenosis. Am. J. Cardiol. 2006, 98:375-382.
53. Ellis S.G., Savage M., Fishman D. Restenosis after placement of Palmaz-Shatz stents in native coronary arteries: initial results of a multicenter experience. Circulation 1992, 86:1836-1844.
54. Falk E. Pathogenesis of atherosclerosis. J. Am. Coll. Cardiol. 2006, 47:C7-C12.
55. Farley A.R., Link A.J. Identification and quantification of protein posttranslational modifications. Methods Enzymol. 2009, 463:725-763.
56. Fenrandez-Hernando C., Jozsef L., Jenkins D., Di Lorenzo A., Sessa W.C. Absence of Akt1 reduces vascular smooth muscle cell migration and survival and induces features of plaque vulnerability and cardiac dysfunction during atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2009, 29:2033-2040.
57. Ferns G.A., Raines E.W., Sprugel K.H., Motani A.S., Reidy M.A., Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991, 253:1129-1132.
58. Fetalvero K.M., Shyu M., Nomikos A.P., Chiu Y.F., Wagner R.J., Powell R.J., et al. The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H1337-H1346.
59. Frimermann A., Welch P.J., Jin X., Eigler N., Yei S., Forrester J., et al. Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model. Circulation 1999, 99:697-703.
60. Gadson P.F., Dalton M.L., Patterson E., Svoboda D.D., Hutchinson L., Schram D., et al. Differential response of mesoderm- and neural crest-derived smooth muscle to TGF-β1: regulation of c-myb and a1 I procollagen genes. Exp. Cell Res. 1997, 230:169-180.
61. Gao B.B., Stuart L., Feener E.P. Label-free quantitative analysis of one-dimensional PAGE LC/MS/MS proteome. Application to Angiotensin II stimulated smooth muscle cell secretome. Mol. Cell Proteomics 2008, 7:2399-2409.
62. García-Arguinzonis M., Padró T., Lugano T., Llorente-Cortes V., Badimon L. Low-density lipoproteins induce heat shock protein 27 dephosphorylation, oligomerization, and subcellular relocalization in human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1212-1219.
63. Geng Y.J., Libby P. Progression of atheroma: a struggle between death and procreation. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1370-1380.
64. Gerthoffer W.T. Mechanism of vascular smooth muscle cell migration. Circ. Res. 2007, 100:607-621.
65. Giachelli C.M., Liaw L., Murry C.E., Schwartz S.M., Almeida M. Osteopontin expression in cardiovascular diseases. Ann. NY Acad. Sci. 1995, 760:109-126.
66. Gittenberger-de Groot A.C., DeRuiter M.C., Bergwerff M., Poelmann R.E. Smooth muscle cell origin and its relation to heterogeneity in development and disease. Arterioscler. Thromb. Vasc. Biol. 1999, 19:1589-1594.
67. Glass C.K., Witztum J.L. Atherosclerosis: the road ahead. Cell 2001, 104:503-516.
68. Gollasch M., Haase H., Ried C., Lindschau C., Morano I., Luft F.C., et al. L-type calcium channel expression depends on the differentiated state of vascular smooth muscle cells. FASEB J. 1998, 12:593-601.
69. Goodlett D.R., Keller A., Watts J.D., Newitt R., Yi E.C., Purvine S., et al. Differential stable isotope labeling of peptides for quantitation and de novo sequence derivation. Rapid Commun. Mass Spectrom. 2001, 15:1214-1221.
70. Grassi G., Grassi M., Platz J., Bauriedel G., Kandolf R., Kuhn A. Selection and characterization of active hammerhead ribozymes targeted against cyclin E and E2F1 full-length mRNA. Antisense Nucleic Acid Drug Dev. 2001, 11:271-287.
71. Gronholdt M.L., Dalager-Pedersen S., Falk E. Coronary atherosclerosis: determinants of plaque rupture. Eur. Heart J. 1998, 19:C24-C29.
72. Gueguen M., Keuylian Z., Mateo V., Mougenot N., Lompré A.M., Michel J.B., et al. Implication of adenylyl cyclase 8 in pathological smooth muscle cell migration occurring in rat and human vascular remodeling. J. Pathol. 2010, 221:331-342.
73. Gunst S.J., Zhang W. Actin cytoskeletal dynamics in smooth muscle: a new paradigm for the regulation of smooth muscle contraction. Am. J. Physiol. Cell Physiol. 2008, 295:C576-C587.
74. Gygi S.P., Rist B., Gerber S.A., Turecek F., Gelb M.H., Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 1999, 17:994-999.
75. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormach M.P., Wulffraat N., Leboulch P., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
76. Hall J.L., Chatham J.C., Eldar-Finkelman H., Gibbons G. Vascular smooth muscle cell apoptosis. Diabetes 2001, 50:1171-1179.
77. Hao H., Ropraz P., Verin V., Camenzind E., Geinoz A., Pepper M.S., et al. Heterogeneity of smooth muscle cell populations cultured from pig coronary artery. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1093-1099.
78. Hao H., Gabbiani G., Bochaton-Piallat M.L. Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1510-1520.
79. Hattan S.J., Parker K.C. Methodology utilising MS signal intensity and LC retention time for quantitative analysis and precursor ion selection in proteomic LC-MALDI analyses. Anal. Chem. 2006, 78:7986-7996.
80. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004, 18:1926-1945.
81. Hayashi K., Takahashi M., Kimura K., Nishida W., Saga H., Sobue K. Changes in the balance of phosphoinositide 3-kinase/protein kinase B AKT and the mitogen-activated protein kinases ERK/p38MAPK determine a phenotype of visceral and vascular smooth muscle cells. J. Cell Biol. 1999, 145:727-740.
82. Higashi Y., Sukhanov S., Anwar A., Shai S.Y., Delafontaine P. IGF-1, oxidative stress and atheroprotection. Trends Endocrinol. Metab. 2010, 21:245-254.
83. Hollander J.M., Martin J.L., Belke D.D., Scott B.T., Swanson E., Krishnamoorthy V., et al. Overexpression of wild-type heat shock protein 27 and a nonphosphorylatable heat shock protein 27 mutant protects against ischemia/reperfusion injury in a transgenic mouse model. Circulation 2004, 110:3544-3552.
84. House S.J., Ginnan R.G., Armstrong S.E., Singer H.A. Calcium/calmodulin-dependent protein kinase II delta isoform regulation of vascular smooth muscle cell proliferation. Am. J. Physiol. Cell Physiol. 2007, 292:C2276-C2287.
85. House S.J., Potier M., Bisaillon J., Singer H.A., Trebak M. The non-excitable smooth muscle: calcium signaling and phenotypic switching during vascular disease. Pflugers. Arch. 2008, 456:769-785.
86. Howarth J.L., Lee Y.B., Uney J.B. Using viral vectors as gene transfer tools. Cell Biol. Toxicol. 2010, 26:1-20.
87. Howe S.J., Mansour M.R., Schwartzwaelder K., Bartholomae C., Hubank M., Kempski H., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukomogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 2008, 118:3143-3150.
88. Hu W.Y., Fukuda N., Nakayama M., Kishioka H., Kanmatsuse K. Inhibition of vascular smooth muscle cell proliferation by DNA-RNA chimeric hammerhead ribozyme targeting to rat platelet-derived growth factor A-chain mRNA. J. Hypertens. 2001, 19:203-212.
89. Hu W.Y., Fukuda N., Kishioka H., Nakayama M., Satoh C., Kanmatsuse K. Hammerhead ribozyme targeting human platelet-derived growth factor A-chain mRNA inhibited the proliferation of human vascular smooth muscle cells. Atherosclerosis 2001, 158:321-329.
90. Hung Y.C., Wang P.W., Pan T.L., Bazylak G., Leu Y.L. Proteomic screening of antioxidant effects exhibited by radix Salvia miltiorrhiza aqueous extract in cultured rat aortic smooth muscle cells under homocysteine treatment. J. Ethnopharmacol. 2009, 124:463-474.
91. Ikeda Y., Imai Y., Kamugai H., Nosaka T., Morikawa Y., Hisaoka T., et al. Vasorin, a transforming growth factor β-binding protein expressed in vascular smooth muscle cells, modulates the arterial response to injury in vivo. Proc. Natl. Acad. Sci. USA 2004, 101:10732-10737.
92. Ishiko K., Sakoda T., Akagami T., Naka T., Doi T., Tsujino T., et al. Hyperglycemia induced cell growth and gene expression via serum response element through RhoA and Rho-kinase smooth muscle cells. Prep. Biochem. Biotechnol. 2010, 40:139-151.
93. Jang W.G., Kim H.S., Park K.G., Park Y.B., Yoon K.H., Han S.W., et al. Analysis of proteome and transcriptome of tumor necrosis factor alpha stimulated vascular smooth muscle cells with or without alpha lipoic acid. Proteomics 2004, 4:3383-3393.
94. Jawien A., Bowen-Pope D.F., Lindner V., Schwartz S.M., Clowes A.W. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J. Clin. Invest. 1992, 89:507-511.
95. Jiang G.J., Han M., Zheng B., Wen J.K. Hyperplasia suppressor gene associates with smooth muscle α-actin and is involved in the redifferentiation of vascular smooth muscle cells. Heart Vessels 2006, 21:315-320.
96. Ji R., Cheng Y., Yue J., Yang J., Liu X., Chen H., et al. MicroRNAs expression signature and antisense-mediated depletion reveal and essential role of miRNA in vascular neointimal lesion formation. Circ. Res. 2007, 100:1579-1588.
97. Jovine S., Hultgardh-Nilsson A., Regnstrom J., Nilsson J. Tumor necrosis factor-alpha activates smooth muscle cell migration in culture and is expressed in balloon-injured rat aorta. Arterioscler. Thromb. Vasc. Biol. 1997, 17:490-497.
98. Kawai-Kowase K., Owens G.K. Multiple Repressor pathways contribute to phenotypic switching of vascular smooth muscle cells. Am. J. Physiol. Cell Physiol. 2007, 292:C59-C69.
99. Keefe A.D., Pai S., Ellington A. Aptamers as therapeutics. Nat. Rev. 2010, 9:537-550.
100. Khatri J.J., Johnson C., Magid R., Lessne S.M., Laude K.M., Dikalov S.I., et al. Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation 2004, 109:520-525.
101. Kim S., Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol. Rev. 2000, 52:11-34.
102. Krishnaswamy G., Kelley J., Yerra L., Smith J.K., Chi D.S. Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J. Interferon Cytokine Res. 1999, 19:91-104.
103. Krützfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., et al. Silencing of microRNAs in vivo with "antagomirs". Nature 2005, 438:685-689.
104. Laplante M., Sabatini D.M. mTOR signaling at a glance. J. Cell Sci. 2009, 122:3589-3594.
105. Larsen M.R., Sorensen G.L., Fey S.J., Larsen P.M., Roepstorff P. Phospho-proteomics: evaluation of the use of enzymatic de-phosphorylation and differential mass spectrometric peptide mass mapping for site specific phosphorylation assignment in proteins separated by gel electrophoresis. Proteomics 2001, 1:223-238.
106. Lee W.C., Lee K.H. Applications of affinity chromatography in proteomics. Anal. Biochem. 2004, 324:1-10.
107. Li X., Van Putten V., Zarinetchi F., Nicks M., Thaler S., Heasley L., et al. Suppression of smooth muscle alpha-actin expression by platelet-derived growth factor in vascular smooth muscle cells involves Ras and cytosolic phospholipase A2. Biochem. J. 1997, 327:709-716.
108. Liao D.F., Jin Z.G., Baas A.S., Daum G., Gygi S.P., Aebersold R., et al. Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J. Biol. Chem. 2000, 275:189-196.
109. Liaw L., Almeida M., Hart C.E., Schwartz S.M., Giachelli C.M. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ. Res. 1994, 74:214-224.
110. Linder M.E., Deschenes R.J. New insights into the mechanisms of protein palmitoylation. Biochemistry 2003, 42:4311-4320.
111. Lipskaia L., Del Monte F., Capiod T., Yacoubi S., Hadri L., Hours M., et al. Sarco/endoplasmic reticulum Ca2+-ATPase gene transfer reduces vascular smooth muscle cell proliferation and neointima formation in the rat. Circ. Res. 2005, 97:488-495.
112. Liu H., Sadygov R.G., Yates J.R. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal. Chem. 2004, 76:4193-4201.
113. Lorraine M.W., Reynolds P.N., Baker A.H. Improved gene delivery to human saphenous vein cells and tissue using a peptide-modified adenoviral vector. Genet. Vaccines Ther. 2004, 2:14-17.
114. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
115. Lutgens E., Gijbels M., Smook M., Heeringa P., Gotwals P., Koteliansky V.E., et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler. Thromb. Vasc. Biol. 2002, 22:975-982.
116. Maier K.G., Han X., Sadowitz B., Gentile K.L., Middleton F.A., Gahtan V. Thrombospondin-1: a proatherosclerotic protein augmented by hyperglycemia. J. Vasc. Surg. 2010, 51:1238-1247.
117. Mallat Z., Gojova A., Marchiol-Fournigault C., Esposito B., Kamate C., Merval R., et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ. Res. 2001, 89:930-934.
118. Mallat Z., Steg P.G., Benessiano J., Tanguy M.L., Fox K.A., Collet J.P., et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J. Am. Coll. Cardiol. 2005, 46:1249-1257.
119. Manabet T. Capillary electrophoresis of proteins for proteomic studies. Electrophoresis 1999, 20:3116-3121.
120. Mano T., Luo Z., Malendowicz S.L., Evans T., Walsh K. Reversal of GATA-6 downregulation promotes smooth muscle differentiation and inhibits intimal hyperplasia in balloon-injured rat carotid artery. Circ. Res. 1999, 84:647-654.
121. Martin K.A., Rzucidlo E.M., Merenick B.L., Fingar D.C., Brown D.J., Wagner R.J., et al. The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. Am. J. Physiol. Cell Physiol. 2004, 286:C507-C517.
122. Mattingly R.R., Gibbs R.A., Menard R.E., Reiners J.J. Potent suppression of proliferation of A10 vascular smooth muscle cells by combined treatment with lovastatin and 3-allylfarnesol, an inhibitor of protein 'transferase'. J. Pharmacol. Exp. Ther. 2002, 303:74-81.
123. Mawji I.A., Marsden P.A. Perturbations in paracrine control of the circulation: role of the endothelial-derived vasomediators, endothelin-1 and nitric oxide. Microsc. Res. Tech. 2003, 60:46-58.
124. Mayr U., Mayr M., Yin X., Begum S., Tarelli E., Wait R., et al. Proteomic dataset of mouse aortic smooth muscle cells. Proteomics 2005, 5:4546-4557.
125. McGregor E., Kempster L., Wait R., Welson S.Y., Gosling M., Dunn M.J., et al. Identification and mapping of human saphenous vein medial smooth muscle proteins by two-dimensional polyacrylamide gel electrophoresis. Proteomics 2001, 11:1405-1414.
126. McGregor E., Kempster L., Wait R., Gosling M., Dunn M.J., Powel J.T. F-actin capping CapZ and other contractile saphenous vein smooth muscle proteins are altered by hemodynamic stress. Mol. Cell. Proteomics 2004, 3:115-124.
127. McLachlin D.T., Chait B.T. Analysis of phosphorylated proteins and peptides by mass spectrometry. Curr. Opin. Chem. Biol. 2001, 5:591-602.
128. Miano J.M., Long X., Fujiwara K. Serum response factor: master regulator of the actin cytoskeleton and contractile apparatus. Am. J. Physiol. Cell Physiol. 2007, 292:C70-C81.
129. Moncada S. Prostacyclin and arterial wall biology. Arteriosclerosis 1982, 2:193-207.
130. Morishita R., Yamada S., Yamamoto K., Tomita N., Kida I., Sakurabayashi I., et al. Novel therapeutic strategy for atherosclerosis. Ribozyme oligonucleotide against apolipoprotein selectively inhibit apolipoprotein but not plasminogen gene expression. Circulation 1998, 98:1898-1904.
131. Morrisey E.E. GATA-6: the proliferation stops here: cell proliferation in glomerular mesangial and vascular smooth muscle cells. Circ. Res. 2000, 87:638-640.
132. Morrow D., Scheller A., Birney Y.A., Sweeney C., Guha S., Cummins P.M., et al. Notch-mediated CBF-1/RBP-Jk-dependent regulation of human vascular smooth muscle cell phenotype in vitro. Am. J. Physiol. Cell Physiol. 2005, 289:C1188-C1196.
133. Neverova I., Van Eyk J.E. Application of reversed phase high performance liquid chromatography for subproteomic analysis of cardiac muscle. Proteomics 2002, 2:22-31.
134. Newby A.C. Dual role of matrix metalloproteinases matrixins in intimal thickening and atherosclerotic plaque rupture. Physiol. Rev. 2005, 85:1-31.
135. Newby A.C., Zaltsman A.B. Fibrous cap formation or destruction the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Cardiovasc. Res. 1999, 41:345-360.
136. Nozawa Y., Matsuura N., Miyake H., Yamada S., Kimura R. Effects of TH-142177 on angiotensin II-induced proliferation, migration and intracellular signaling in vascular smooth muscle cells and on neointimal thickening after balloon injury. Life Sci. 1999, 64:2061-2070.
137. Oda Y., Huang K., Cross F.R., Cowburn D., Chait B.T. Accurate quantitation of protein expression and site-specific phosphorylation. Proc. Natl. Acad. Sci. USA 1999, 96:6591-6596.
138. Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006, 127:635-648.
139. Omenn G.S., States D.J., Adamski M., Blackwell T.W., Menon R., Hermjakob H., et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5:3226-3245.
140. Ong S.E., Mann M. A practical recipe for stable isotope labeling by amino acids in cell culture SILAC. Nat. Protoc. 2006, 1:2650-2660.
141. Ong A.T., Serruys P.W. Technology insight: an overview of research in drug-eluting stents. Nat. Clin. Pract. Cardiovasc. Med. 2005, 12:647-658.
142. Ong S.E., Blagoev B., Kratchmarova I., Kristensen D.B., Steen H., Pandey A., et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 2002, 1:376-386.
143. Ono H., Ichiki T., Fukuyama K., Iino N., Masuda S., Egashira K., et al. cAMP-response element binding protein mediates tumor necrosis factor-a-induced vascular smooth muscle cell migration. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1-8.
144. Opiteck G.J., Ramírez S.M., Jorgenson J.W., Moseley M.A. Comprehensive two-dimensional high-performance liquid chromatography for the isolation of over-expressed proteins and proteome mapping. Anal. Biochem. 1998, 258:349-361.
145. Owens G.K. Regulation of differentiation of vascular smooth muscle cells. Physiol. Rev. 1995, 75:487-517.
146. Owens G.K., Geisterfer A.A., Yang Y.W., Komoriya A. Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells. J. Cell Biol. 1988, 107:771-780.
147. Owens G.K., Kumar M.S., Wamhoff N.R. Molecular regulation of vascular smooth muscle cell differetiation in development and disease. Physiol. Rev. 2004, 84:767-801.
148. Packard R.S., Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin. Chem. 2008, 54:24-38.
149. Padrò T., Peña E., Garcia-Arguinzonis M., Lorente-Cortes V., Badimon L. Low-density lipoproteins impair migration of human coronary vascular smooth muscle cells and induce changes in the proteomic profile of myosin light chain. Cardiovasc. Res. 2007, 77:211-220.
150. Palmer R.M., Rees D.D., Ashton D.S., Moncada S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem. Biophys. Res. Commun. 1988, 30:1251-1256.
151. Panchatcharam M., Miriyala S., Yang F., Leitges M., Chrzanowska-Wodnicka M., Quillam L.A., et al. Enhanced proliferation and migration of vascular smooth cells in response to vascular injury under hyperglycemic conditions is controlled by β3 integrin signaling. Int. J. Biochem. Cell Biol. 2010, 42:965-974.
152. Panda D., Kundu G.C., Lee B.I., Peri A., Fohl D., Chackalaparampil I., et al. Potential roles of osteopontin and alphaVbeta3 integrin in the development of coronary artery restenosis after angioplasty. Proc. Natl. Acad. Sci. USA 1997, 94:9308-9313.
153. Paoletti A.C., Washburn M.P. Quantitation in proteomics experiments utilizing mass spectrometry. Biotechnol. Genet. Eng. Rev. 2006, 22:1-19.
154. Patel V.J., Thalassinos K., Slade S.E., Connolly J.B., Crombie A., Murrell J.C., et al. A comparison of labeling and label-free mass spectrometry-based proteomics approaches. J. Proteome Res. 2009, 8:3752-3759.
155. Patton W.F., Erdjument-Bromage H., Marks A.R., Tempst P., Taubman M.B. Components of the protein synthesis and folding machinery are induced in vascular smooth muscle cells by hypertrophic and hyperplastic agents. Identification by comparative protein phenotyping and microsequencing. J. Biol. Chem. 1995, 270:21404-21410.
156. Pawson T. Regulation and targets of receptor tyrosine kinases. Eur. J. Cancer 2002, 38:S3-S10.
157. Perlman H., Sata M., Krasinski K., Dorai T., Buttyan R., Walsh K. Adenovirus-encoded hammerhead ribozyme to Bcl-2 inhibits neointimal hyperplasia and induces vascular smooth muscle cell apoptosis. Cardiovasc. Res. 2000, 45:570-578.
158. Pintucci G., Yu P.J., Saponara F., Kadian-Dodov D.L., Galloway A.C., Mignatti P. PDGF-BB induces vascular smooth muscle cell expression of high molecular weight FGF-2, which accumulates in the nucleus. J. Cell. Biochem. 2005, 95:1292-1300.
159. Pipes G.C., Creemers E.E., Olson E. The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes Dev. 2006, 20:1545-1556.
160. Poliseno L., Cecchettini A., Mariani L., Evangelista M., Ricci F., Giorgi F., et al. Resting smooth muscle cells as a model for studying vascular cell activation. Tissue Cell 2006, 38:111-120.
161. Ponnazhagan S., Mukerjee P., Yoder M.C., Wang X.S., Zhou S.Z., Kaplan J., et al. Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. Gene 1997, 190:203-210.
162. Powell R.J., Bhargava J., Basson M.D., Sumpio B.E. Coculture conditions alter endothelial modulation of TGF-beta 1 activation and smooth muscle growth morphology. Am. J. Physiol. 1998, 274:H642-H649.
163. Pyle A.L., Young P.P. Atheromas feel the pressure. Biochemical stress and atherosclerosis. Am. J. Pathol. 2010, 177:4-9.
164. Qin H., Ishiwata T., Wang R., Kudo M., Yokoyama M., Naito Z., et al. Effects of extracellular matrix on phenotype modulation and MAPK transduction of rat aortic smooth muscle cells in vitro. Exp. Mol. Pathol. 2000, 69:79-90.
165. Radhakrishnan Y., Maile L.A., Ling Y., Graves L.M., Clemmons D.R. Insulin-like growth factor-1 stimulates Shc-dependent phosphatidylinositol 3-kinase activation via Grb2-associated p85 in vascular smooth muscle cells. J. Biol. Chem. 2008, 283:16320-16331.
166. Radhakrishnan Y., Busby W.H., Shen X., Maile L.A., Clemmons D.R. Insulin-like growth factor-1 stimulated insulin receptor substrate-1 negatively regulated Src homology 2 domain-containing protein-tyrosine phosphatase substrate-1 function in vascular smooth muscle cells. J. Biol. Chem. 2010, 21:15682-15695.
167. Raman P., Krukovets I., Marinic T.E., Bornstein P., Stenina O.I. Glycosylation mediates up-regulation of a potent antiangiogenic and proatherogenic protein, thrombospondin-1, by glucose in vascular smooth muscle cells. J. Biol. Chem. 2007, 282:5704-5714.
168. Rocchiccioli S., Citti L., Boccardi C., Ucciferri N., Tedeschi L., Lande C., et al. A gel-free approach in vascular smooth muscle cell proteome: perspectives for a better insight into activation. Proteome Sci. 2010, 8:15.
169. Ross R. The pathogenesis of atherosclerosis. Nature 1993, 362:801-809.
170. Ross R. Atherosclerosis an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
171. Ross R., Glomset J.A. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973, 180:1332-1339.
172. Ross P.L., Huangh Y.N., Marchese J.N., Williamson B., Parker K., Hattan S., et al. Multiplexed protein quantitation in saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 2004, 3:1154-1169.
173. Sarbassov D.D., Ali S.M., Sabatini D. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 2005, 17:596-603.
174. Sarkar J., Gou D., Turaka P., Viktorova E., Ramchandran R., Raj J.U. MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010, 299, L861-871.
175. Sartore S., Chiavegato A., Faggin E., Franch R., Puato M., Ausoni S., et al. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ. Res. 2001, 89:1111-1121.
176. Sata M., Saiura A., Kunisato A., Tojo A., Okada S., Tokuhisa T., et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat. Med. 2002, 8:403-409.
177. Scalbert E., Bril A. Implication of microRNAs in the vascular system. Curr. Opin. Pharmacol. 2008, 8:181-188.
178. Sekiguchi K., Kurabayashi M., Oyama Y., Aihara Y., Tanaka T., Sakamoto H., et al. Homeobox protein Hex induces Smemb/Nonmuscle myosin heavy ch-B gene expression through the cAMP-responsive element. Circ. Res. 2001, 88:52-58.
179. Seo J., Lee K.J. Post-translational modifications and their biological functions: proteomic analysis and systematic approaches. J. Biochem. Mol. Biol. 2004, 37:35-44.
180. Shen X., Xi G., Radhakrishnan Y., Clemmons D.R. Recruitment of Pyk2 to SHPS-1 signaling complex is required for IGF-I-dependent mitogenic signaling in vascular smooth muscle cells. Cell. Mol. Life Sci. 2010, 67:3893-3903.
181. Shin E.Y., Lee C.S., Park M.E., Kim D.J., Kwak S.J., Kim E.G. Involvement of βPIX in angiotensin II-induced migration of vascular smooth muscle cells. Exp. Mol. Med. 2009, 41:387-396.
182. Shlomi T., Berkman O., Ruppin E. Regulatory on/off minimization of metabolic flux changes after genetic perturbations. Proc. Natl. Acad. Sci. USA 2005, 102:7695-7700.
183. Silva J.C., Denny R., Dorschel C.A., Gorenstein M.V., Kass I.J., Li G.Z., et al. Quantitative proteomic analysis by accurate mass retention time pairs. Anal. Chem. 2005, 77:2187-2200.
184. Silva J.C., Denny R., Dorschel C., Gorenstein M.V., Li G.Z., Richardson K., et al. Simultaneous qualitative and quantitative analysis of the Escherichia coli proteome: a sweet tale. Mol. Cell. Proteomics 2006, 5:589-607.
185. Silva J.C., Gorenstein M.V., Li G.Z., Vissers J.P.C., Geromanos S.J. Absolute quantification of proteins by LCMS: a virtue of parallel MS acquisition. Mol. Cell. Proteomics 2006, 5:144-156.
186. Simper D., Stalboerger P.G., Panetta C.J., Wang S., Caplice N.M. Smooth muscle progenitor cells in human blood. Circulation 2002, 106:1199-1204.
187. Sirlin J.L. On the incorporation of methionine 35S into proteins detectable by autoradiography. J. Histochem. Cytochem. 1958, 6:185-190.
188. Song Z., Li G. Role of specific microRNAs in regulation of vascular smooth muscle cell differentiation and the response to injury. J. Cardiovasc. Trans. Res. 2010, 3:246-250.
189. Spiegel S., Milstien S. Sphingosine-1-phosphate: an enigmatic signaling lipid. Nat. Rev. Mol. Cell Biol. 2003, 4:397-407.
190. Stintzing S., Ocker M., Hartner A., Amann K., Barbera L., Neureiter D. Differentiation patterning of vascular smooth muscle cells VSMC in atherosclerosis. Virchows Arch. 2009, 455:171-185.
191. Stocker R., Keaney J.F. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 2004, 84:1381-1478.
192. Su J.Z., Fukuda N., Hu W.Y., Kanmatsuse K. Ribozyme to human TGF-beta1 mRNA inhibits the proliferation of human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 2000, 278:401-407.
193. Sui J., Zhang J., Tan T.L., Ching C.B., Chen W.N. Comparative proteomics analysis of vascular smooth muscle cells incubated with S- and R-enantiomers of atenolol using iTRAQ-coupled two-dimensional LC-MS/MS. Mol. Cell. Proteomics 2008, 7:1007-1018.
194. Sukhanov S., Higashi Y., Shai S.Y., Vaughn C., Mohler J., Li Y., et al. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2684-2690.
195. Sykora C., Hoffmann R., Hoffmann P. Enrichment of multiphosphorylated peptides by immobilized metal affinity chromatography using GaIII- and FeIII-complexes. Protein Pept. Lett. 2007, 14:489-496.
196. Takuwa Y. Subtype-specific differential regulation of Rho family G proteins and cell migration by the Edg family sphingosine-1-phosphate receptors. Biochim. Biophys. Acta 2002, 1582:112-120.
197. Takuwa Y., Okamoto Y., Yoshioka K., Takuwa N. Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system. Biochim. Biophys. Acta 2008, 1781:483-488.
198. Tang D.D., Anfinogenova Y. Physiologic properties and regulation of the actin cytoskeleton in vascular smooth muscle. J. Cardiovasc. Pharmacol. Ther. 2008, 13:130-140.
199. Tang J., Kozaki K., Farr A.G., Martin P.J., Lindahl P., Betsholtz C., et al. The absence of platelet-derived growth factor-B in circulating cells promotes immune and inflammatory responses in atherosclerosis-prone ApoE-/- mice. Am. J. Pathol. 2005, 167:901-912.
200. Tanizawa S., Ueda M., van der Loos C.M., van der Wal A.C., Becker A.E. Expression of platelet derived growth factor B chain and beta receptor in human coronary arteries after percutaneous transluminal coronary angioplasty: an immunohistochemical study. Heart 1996, 75:549-556.
201. Tashiro H., Shimokawa H., Sadamatsu K., Aoki T., Yamamoto K. Role of cytokines in the pathogenesis of restenosis after percutaneous transluminal coronary angioplasty. Coron. Artery Dis. 2001, 12:107-113.
202. Taurin S., Seyrantepe V., Orlov S.N., Tremblay T.L., Thibault P., Bennett M.R., et al. Proteome analysis and functional expression identify mortalin as an antiapoptotic gene induced by elevation of [Na+]i/[K+]i ratio in cultured vascular smooth muscle cells. Circ. Res. 2002, 91:915-922.
203. Tchivilev I., Madamanchi N.R., Vendrov A.E., Niu X.L., Runge M.S. Identification of a protective role for protein phosphatase 1cy1 against oxidative stress-induced vascular smooth muscle cell apoptosis. J. Biol. Chem. 2008, 283:22193-22205.
204. Tedeschi L., Lande C., Cecchettini A., Citti L. Hammerhead ribozymes in therapeutic target discovery and validation. Drug Discov. Today 2009, 14:776-783.
205. Teng J., Fukuda N., Hu W.Y., Nakayama M., Kishioka H., Kanmatsuse K. DNA-RNA chimeric hammerhead ribozyme to transforming growth factor-beta1 mRNA inhibits the exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats. Cardiovasc. Res. 2000, 48:138-147.
206. Thingholm T.E., Jorgensen T.J., Jensen O.N., Larsen M.R. Highly selective enrichment of phosphorylated peptides using titanium dioxide. Nat. Protoc. 2006, 1:1929-1935.
207. Thingholm E.T., Jensen O.N., Robinson P.J., Larsen M.R. SIMAC Sequential Elution from IMAC, a phosphoproteomics strategy for the rapid separation of monophosphorylated from multiply phosphorylated peptides. Mol. Cell. Proteomics 2008, 7:661-671.
208. Thingholm T.E., Jensen O.N., Larsen M.R. Analytical strategies for phosphoproteomics. Proteomics 2009, 9:1451-1468.
209. Tian Y., Sommerville L., Cuneo A., Kelemen S., Autieri M. Expression and suppressive effects of interleukin-19 on vascular smooth muscle cell pathophysiology and development of intimal hyperplasia. Am. J. Pathol. 2008, 173:901-909.
210. Tjalsma H., Bolhuis A., Jongbloed J.D., Bron S., Van Dijl J.M. Signal peptide-dependent protein transport in Bacillus subtilis: a genome-based survey of the secretome. Microbiol. Mol. Biol. Rev. 2000, 64:515-547.
211. Trott D., McManus C.A., Martin J.L., Brennan B., Dunn M.J., Rose M.L. Effect of phosphorylated hsp27 on proliferation of human endothelial and smooth muscle cells. Proteomics 2009, 9:3383-3394.
212. Unlu M., Morgan M.E., Minden J.S. Difference gel electrophoresis. A single gel method for detecting changes in protein extracts. Electrophoresis 1997, 18:2071-2077.
213. Vallot O., Combettes L., Jourdon P., Inamo J., Marty I., Claret M., et al. Intracellular Ca2+ handling in vascular smooth muscle cells is affected by proliferation. Arterioscler. Thromb. Vasc. Biol. 2000, 20:1225-1235.
214. Van Montfort R.L., Congreve M., Tisi D., Carr R., Jhoti H. Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1b. Nature 2003, 423:773-777.
215. Volpers C., Kochanek S. Adenoviral vectors for gene transfer and therapy. J. Gene Med. 2004, 6:S164-S171.
216. Wada H., Hasegawa K., Morimoto T., Kakita T., Yanazume T., Abe M., et al. Calcineurin-GATA-6 pathway is involved in smooth muscle-specific transcription. J. Cell Biol. 2002, 156:983-991.
217. Wang Z., Newman W.H. Smooth muscle cell migration stimulated by interleukin 6 is associated with cytoskeletal reorganization. J. Surg. Res. 2003, 111:261-266.
218. Wang Y., Flores L., Lu S., Miao H., Li Y.S., Chien S. Shear stress regulates the Flk-1/Cbl/PI3K/NF-kB pathway via actin and tyrosine kinases. Cell. Mol. Bioeng. 2009, 1:341-350.
219. Wang Z., Kong L., Kang J., Vaughn D.M., Bush G.D., Walding A.L., et al. Interleukin-Ibeta induces migration of rat arterial smooth muscle cells through a mechanism involving increased matrix metalloproteinase-2 activity. J. Surg. Res. 2010, 10.1016/j.jss.2009.12.010.
220. Wang Y., Zhang B., Bai Y., Zeng C., Wang X. Changes in proteomic features induced by insulin on vascular smooth muscle cells from spontaneous hypertensive rats in vitro. Cell Biochem. Biophys. 2010, 58:97-106.
221. Welser J.V., Lange N., Singer C.A., Elorza M., Scowen P., Keef K.D., et al. Loss of α7 integrin promotes extracellular signal-regulated kinase activation and altered vascular remodeling. Circ. Res. 2007, 101:672-681.
222. White K., Nicklin S.A., Baker A.H. Novel vectors for in vivo gene delivery to vascular tissue. Expert Opin. Biol. Ther. 2007, 7:809-821.
223. Williams P.D., Ranjzad P., Kakar S., Kingston P.A. Development of viral vectors for use in cardiovascular gene therapy. Viruses 2010, 2:334-371.
224. Winkler J., Stess M., Amartey J., Noe C. Off-target effects related to the phosphorothionate modification of nucleic acids. Chem. Med. Chem. 2010, 5:1344-1352.
225. Woo H.A., Chae H.Z., Hwang S.C., Yang K.S., Kang S.W., Kim K., et al. Reversing the inactivation of peroxiredoxins caused by cysteine sulfinic acid formation. Science 2003, 300:653-656.
226. Wu Z., Yang H., Colosi P. Effect of genome size on AAV vector packaging. Mol. Ther. 2009, 18:80-86.
227. Wu X., Cheng J., Li P., Yang M., Qiu S., Liu P., et al. Mechano-sensitive transcriptional factor Egr-1 regulates insulin-like growth factor-1 receptor expression and contributes to neointima formation in vein grafts. Arterioscler. Thromb. Vasc. Biol. 2010, 30:471-476.
228. Yamada H., Tsushima T., Murakami H., Uchigata Y., Iwamoto Y. Potentiation of mitogenic activity of platelet-derived growth factor by physiological concentrations of insulin via the MAP kinase cascade in rat A10 vascular smooth muscle cells. Int. J. Exp. Diabetes Res. 2002, 3:131-144.
229. Yano H., Kuroda S., Buchanan B.B. Disulfide proteome in the analysis of protein function and structure. Proteomics 2002, 2:1090-1096.
230. Zaiss A.K., Machado H.B., Herschman H.R. The influence of innate and pre-existing immunity to adenovirus therapy. J. Cell. Biochem. 2009, 7:778-790.
231. Zargham R., Touyz R.M., Thibault G. α-8 Integrin overexpression in de-differentiated vascular smooth muscle cells attenuates migratory activity and restores the characteristics of the differentiated phenotype. Atherosclerosis 2007, 195:303-312.
232. Zhang C. microRNAs: role in cardiovascular biology and disease. Clin. Sci. 2008, 114:699-706.
233. Zhang C. microRNA-145 in vascular smooth muscle cell biology: a new therapeutic target for vascular disease. Cell Cycle 2009, 8:3469-3473.
234. Zhang Y., Wolf-Yadlin A., Ross P.L., Pappin D.J., Rush J., Lauffenburger D.A., et al. Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol. Cell. Proteomics 2005, 4:1240-1250.
235. Zheng J.P., Ju D., Shen J., Yang M., Li L. Disruption of actin cytoskeleton mediates loss of tensile stress induced early phenotypic modulation of vascular smooth muscle cells in organ culture. Exp. Mol. Pathol. 2009, 88:52-57.
236. Zolotarjova N., Martosella J., Nicol G., Bailey J., Boyes B.E., Barrett W.C. Differences among techniques for high-abundant protein depletion. Proteomics 2005, 5:3304-3313.
237. Zuckerbraun B.S., Stoyanovsky D.A., Sengupta R., Shapiro R.A., Ozanich B.A., Rao J., et al. Nitric oxide-induced inhibition of smooth muscle cell proliferation involves S-nitrosation and inactivation of RhoA. Am. J. Physiol. Cell Physiol. 2007, 292:C824-C831.